Merrimack Pharmaceuticals Inc (MACK)
14.71
-0.02
(-0.14%)
USD |
NASDAQ |
Apr 24, 16:00
14.73
+0.02
(+0.14%)
Pre-Market: 20:00
Merrimack Pharmaceuticals Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2015 | -1.401 |
| September 30, 2015 | -0.8945 |
| June 30, 2015 | -0.8663 |
| March 31, 2015 | -0.9448 |
| December 31, 2014 | -1.175 |
| September 30, 2014 | -1.19 |
| June 30, 2014 | -1.507 |
| March 31, 2014 | -1.725 |
| December 31, 2013 | -2.569 |
| September 30, 2013 | -6.846 |
| June 30, 2013 | -0.6982 |
| Date | Value |
|---|---|
| March 31, 2013 | -1.258 |
| December 31, 2012 | -6.116 |
| September 30, 2012 | 0.00 |
| June 30, 2012 | 0.00 |
| March 31, 2012 | 0.00 |
| December 31, 2011 | 0.00 |
| September 30, 2011 | 0.00 |
| June 30, 2011 | 0.00 |
| March 31, 2011 | 0.00 |
| December 31, 2010 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| NovaBay Pharmaceuticals Inc | 0.3431 |
| Palatin Technologies Inc | 0.00 |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
| Oragenics Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 19.19M |
| Total Liabilities (Quarterly) | 0.441M |
| Shareholders Equity (Quarterly) | 18.75M |